Founded and headquartered in Brisbane, Australia, ImpediMed is a global company with operations in the United States and Europe. We are the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the noninvasive clinical assessment and monitoring of fluid status and tissue composition.
ImpediMed produces a portfolio of FDA-cleared and CE-marked medical devices, including SOZO® for multiple indications, including heart failure and lymphedema, sold in select markets globally. ImpediMed’s connected digital health platform and large, attractive and growing markets present an opportunity for continued strong growth through its SOZO SaaS subscription-based business.
Share register agent
ImpediMed Limited is listed on the Australian Stock Exchange (ASX). Trading in its securities is under the ticker code on ASX of “IPD” for ordinary shares.
To update shareholder contact information or submit transfer documents, please contact ImpediMed’s share register service provider:
Locked Bag A14
NSW 1235, Australia
Shares may be bought on market through any Australian stock broker, or through on-market trades, via a number of international brokerage houses. If you are a potential investor needing information on how to trade in shares through an international brokerage house, please contact:
Morten Vigeland, Chief Financial Officer
ImpediMed maintains an active communications program with investors and the market. If you are interested in a presentation, please contact:
Rick Carreon, Chief Executive Officer